ProCE Banner Activity

CME

Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice

Text Module

In this module, Patricia LoRusso, DO, PhD(h), reviews the current guidelines and recommendations for molecular testing in advanced BTC, explains the rationale for targeting MDM2/p53 signaling in BTC and provides expert perspectives on the potential future role of MDM2 inhibitors in BTC.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2024

Expiration: February 28, 2025

Share

Faculty

Patricia LoRusso

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

PT Faculty

Timothy Scialla

Timothy Scialla, MD

Associate Professor
Division of Pulmonary, Allergy, and Critical Care Medicine
Department of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia

Chetasi Talati

Chetasi Talati, MD

Assistant Professor
Department of Oncologic Sciences
Assistant Member
Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Jill Taylor

Jill Taylor

Contributing Writer

Ashutosh Wechalekar

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This program is intended for oncologists and other healthcare professionals caring for BTC patients.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Bilary tract cancer.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe the rationale for the MDM2-p53 pathway as a therapeutic target in BTC, considering the mechanisms of action of MDM2 inhibitors

  • Evaluate ongoing clinical trial research investigating novel agents and treatment strategies that incorporate MDM2 inhibitor therapies for patients with BTC

  • Identify patients for clinical trials investigating agents targeting the MDM2-p53 pathway in BTC and other tumors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

Patricia LoRusso, DO, PhD(h): advisor: Actuate Therapeutics, Atreca Development, Boehringer Ingelheim, Cullinan, I-Mab, ImCheck, Kineta, Mekanistic, Mersana, Molecular Templates, NeuroTrials, Qualigen, Quanta Therapeutics, Pfizer, Relay Therapeutics, Seagen, Scenic Biotech, Schrodinger, STCube Pharma, Stemline, Takeda; consultant: I-Mab, Roivant Sciences; data and safety monitoring board: Amgen, DrenBio, Sotio.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 29, 2024, through February 28, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.